Create
Log in
Enquire now
Enterome
Developer of OncoMimics™ immunotherapy to treat follicular lymphoma.
Overview
Structured Data
Issues
Contributors
Access by API
Access by API
Is a
Company
Organization
B2X
B2B
Board of Directors
Mary Thistle
Lars Gredsted
Hans-Juergen Woerle
Roger Garceau
Pierre Cassigneu
Georges Gemayel
Pierre Belichard
Isabelle de Cremoux
Luca Marini
CEO
Pierre Belichard
CFO
Christelle Dumoussaud
Company Operating Status
Active
Competitors
Viome
Country
France
Crunchbase URL
crunchbase.com/organiz...enterome
Date Incorporated
2008
Email Address
media@enterome.com
Founded Date
2012
Founder
Stanislav Dusko EHRLICH
Pierre Belichard
Full Address
94/96 avenue Ledru-Rollin 75011 Paris France
Headquarters
Paris
Industry
Microbiome
Therapeutics
Deep Tech
Health technology
Drug discovery
Biotechnology
Medical diagnostics
Pharmaceutical industry
Engineering
Biopharmaceutical
•••
Investors
Symbiosis
Takeda Pharmaceutical Company
Health for Life Capital fund
Nestlé Health Science
Symbiosis LLC
Principia SGR
Omnes Capital
Seventure Partners
Bristol-Myers Squibb
Nestle Health Science
•••
Latest Funding Round Date
June 12, 2025
Latest Funding Round Amount (USD)
19,000,000
Latest Funding Type
Series F
LinkedIn URL
@company/enterome
Location
Paris
United States
Massachusetts
France
Cambridge, Massachusetts
Number of Employees (Ranges)
51 – 200
Patents Assigned (Count)
1
Phone Number
+33175772785
Pitchbook URL
pitchbook.com/profiles.../54111-79
Spun Out From
MetaGenoPolis
Total Funding Amount (USD)
351,521,000
Twitter URL
@enteromesa
Official Website
enterome.com
Find more companies like Enterome
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE